key: cord-0708999-ak29bvj8
authors: Adderley, Patton; Sixon, Joshua; Hodgin, Katherine
title: FROM HOME TO ECMO: A CASE OF NEW-ONSET CARDIOMYOPATHY IN A PATIENT WITH POST-COVID-19 INFECTION
date: 2021-10-31
journal: Chest
DOI: 10.1016/j.chest.2021.07.912
sha: 63f193b4b45cf3e416881b0d2eea529efb7d512a
doc_id: 708999
cord_uid: ak29bvj8

nan

cases rises globally, the gamut of its related complications is rapidly being described in the literature. While typically involving the pulmonary system, COVID-19 can also affect the cardiovascular system. One such complication is COVID-19-related myocarditis, which is thought to be due to a combination of direct viral injury and indirect damage from the host's immune response (Lee). Here, we describe a case of newonset acute heart failure requiring extracorporeal membrane oxygenation (ECMO) post COVID-19 infection.

A 50-year-old African American male with poorly controlled type 2 diabetes presented to hospital with fever, chills, dyspnea and productive cough 2 weeks after positive COVID-19 test in the community. On presentation, patient was hypoxic with oxygen saturation of 88% on room air. Work-up revealed leukocytosis, elevated inflammatory markers, and extensive bilateral infiltrates on chest x-ray. Troponin was elevated at 0.104. Repeat COVID-19 test was negative. Patient was admitted and managed for community acquired pneumonia with ceftriaxone and azithromycin as well as COVID-19 pneumonia with remdesivir, convalescent plasma and dexamethasone. Over the next three days, he experienced significant respiratory decompensation requiring intubation, mechanical ventilation and ICU transfer. He then developed mixed shock (cardiogenic, obstructive, and septic) with transesophageal echocardiogram revealing reduced left ventricular ejection fraction (EF) of 45% and right ventricular strain. Repeat study the next day revealed EF of 20%. CT pulmonary angiogram demonstrated subsegmental pulmonary embolism. As a result, the patient was placed on veno-arterial extracorporeal membrane oxygenation which was later converted to veno-venous. After three weeks of support with ECMO, he was successfully weaned and decannulated. Repeat echocardiogram showed improvement in EF to 65%. Notably, he remained COVID negative (nine negative tests in total).

This case demonstrated cardiovascular and thromboembolic complications in a post-COVID-19 infected patient. While our patient initially tested positive in the community, all subsequent tests were negative implying a post-COVID cardiovascular syndrome. One meta-analysis examining 21 studies showed that cardiovascular complications in COVID-19 patients are strongly associated with death (Sabatino). The decision to use ECMO was based on the patient's worsening respiratory status on optimal mechanical ventilation settings and worsening hemodynamics.

CONCLUSIONS: Improvement in our patient's EF demonstrates that ECMO may offer therapeutic benefit in viral pandemics. However, while it has been utilized in previous viral outbreaks such as H1N1, there is currently inadequate data regarding proper patient selection, outcomes, and efficacy of ECMO use during the COVID-19 pandemic. 

Current concepts in the diagnosis and management of cytokine release syndrome